meRfi®-GM
Cancer / Tumors & Glycosylation
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Three main changes can be found in cancer:
- N-glycans showing often an increased branching due to increased Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A (MAGT5) expression
- Truncation of O-glycans and the exposure of new Tumor-associated carbohydrates (TACA) including the T antigen, Tn antigen and the sialylTn antigen (STn).
- Changes of [sialylation](br…
References (Sources)
- An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas
- Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis
- Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific antiMUC1 antibody responses and override tolerance
- Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer
- Glycobiology of immune responses
- Glycosylation defining cancer cell motility and invasiveness
- Targeting Glycosylation: A New Road for Cancer Drug Discovery